GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Mmp2 | affects expression | EXP | | 6480464 | CTD | Doxorubicin affects the expression of MMP2 mRNA; Doxorubicin affects the expression of MMP2 protein | PMID:19801496 | Mmp2 | decreases expression | EXP | | 6480464 | CTD | Doxorubicin results in decreased expression of MMP2 mRNA; Doxorubicin results in decreased expression of MMP2 protein | PMID:19357873 | Mmp2 | increases activity | EXP | | 6480464 | CTD | Doxorubicin results in increased activity of MMP2 protein | PMID:16213474 PMID:25816614 | Mmp2 | increases expression | EXP | | 6480464 | CTD | Doxorubicin results in increased expression of MMP2 mRNA; Doxorubicin results in increased expression of MMP2 protein | PMID:16213474 PMID:19915844 PMID:20051877 PMID:27087047 PMID:30588110 | Mmp2 | multiple interactions | EXP | | 6480464 | CTD | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased activity of MMP2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP2 mRNA]; benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP2 protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; corvitin inhibits the reaction [Doxorubicin results in increased activity of MMP2 protein]; diphenyleneiodonium inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; Ketoglutaric Acids inhibits the reaction [Doxorubicin results in increased activity of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased activity of MMP2 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; Razoxane inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; Tretinoin inhibits the reaction [Doxorubicin results in decreased expression of MMP2 mRNA]; Tretinoin inhibits the reaction [Doxorubicin results in decreased expression of MMP2 protein] | PMID:16213474 PMID:19357873 PMID:19915844 PMID:20051877 PMID:25816614 PMID:27087047 PMID:30588110 | Mmp2 | affects expression | ISO | MMP2 (Homo sapiens) | 6480464 | CTD | Doxorubicin affects the expression of MMP2 mRNA | PMID:29803840 | Mmp2 | affects response to substance | ISO | MMP2 (Homo sapiens) | 6480464 | CTD | MMP2 affects the susceptibility to Doxorubicin | PMID:16458935 | Mmp2 | decreases expression | ISO | MMP2 (Homo sapiens) | 6480464 | CTD | Doxorubicin results in decreased expression of MMP2 mRNA; Doxorubicin results in decreased expression of MMP2 protein | PMID:33507000 | Mmp2 | decreases expression | ISO | Mmp2 (Mus musculus) | 6480464 | CTD | Doxorubicin results in decreased expression of MMP2 mRNA | PMID:15033991 | Mmp2 | increases expression | ISO | Mmp2 (Mus musculus) | 6480464 | CTD | Doxorubicin results in increased expression of MMP2 mRNA | PMID:16455267 PMID:19286953 | Mmp2 | multiple interactions | ISO | MMP2 (Homo sapiens) | 6480464 | CTD | [AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA; [AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein; [Doxorubicin co-treated with Melatonin] results in decreased expression of MMP2 protein; [Doxorubicin co-treated with tanshinone] affects the expression of MMP2 protein; Doxorubicin promotes the reaction [Melatonin results in decreased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein]; WAY-262611 affects the reaction [[Doxorubicin co-treated with tanshinone] affects the expression of MMP2 protein] | PMID:25686905 PMID:32886829 PMID:33507000 | Mmp2 | multiple interactions | ISO | Mmp2 (Mus musculus) | 6480464 | CTD | 5,10,15,20-tetrakis(N-methyl-4'-pyridyl)porphyrinato-iron(III) inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA] | PMID:19286953 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |